{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:33:56Z","timestamp":1790231636334,"version":"4.1.0"},"reference-count":35,"publisher":"The Endocrine Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Context:<\/jats:title><jats:p>Proprotein convertase subtilisin\/kexin 9 (PCSK9) is known to be a good target to decrease LDL cholesterol (LDL-C) and two forms of PCSK9, mature and furin-cleaved PCSK9, circulate in blood. However, it has not been clarified whether and how the levels of each PCSK9 are affected by LDL-apheresis (LDL-A) treatment, a standard therapy in patients with severe forms of familial hypercholesterolemia (FH).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>Our objective was to investigate the differences in LDL-A-induced reduction of mature and furin-cleaved PCSK9 between homozygous and heterozygous FH, and between dextran sulfate (DS) cellulose adsorption and double membrane (DM) columns and to clarify the mechanism of their removal.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design:<\/jats:title><jats:p>A sandwich ELISA to measure two forms of PCSK9s using monoclonal antibodies was developed. Using the ELISA, PCSK9 levels were quantified before and after LDL-A with DS columns in 7 homozygous and 11 heterozygous FH patients. A crossover study between the two column types was performed. The profiles of PCSK9s were analyzed after fractionation by gel filtration chromatography. Immunoprecipitation of apolipoprotein B (apoB) in FH plasma was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Both mature and furin-cleaved PCSK9s were significantly decreased by 55\u201356% in FH homozygotes after a single LDL-A treatment with DS columns, and by 46\u201348% or 48\u201356% in FH heterozygotes after treatment with DS or DM columns. The reduction ratios of LDL-C were strongly correlated with that of PCSK9 in both FH homozygotes and heterozygotes. In addition, more than 80% of plasma PCSK9s were in the apoB-deficient fraction and a significant portion of mature PCSK9 was bound to apoB, as shown by immunoprecipitation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Both mature and furin-cleaved PCSK9s were removed by LDL-A in homozygous and heterozygous FH either by binding to apoB or by other mechanisms. The ELISA method to measure both forms of plasma PCSK9 would be useful for investigating physiological or pathological roles of PCSK9.<\/jats:p><\/jats:sec>","DOI":"10.1210\/jc.2014-3066","type":"journal-article","created":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T16:49:09Z","timestamp":1413305349000},"page":"E41-E49","source":"Crossref","is-referenced-by-count":52,"title":["Removal of Plasma Mature and Furin-Cleaved Proprotein Convertase Subtilisin\/Kexin 9 by Low-Density Lipoprotein-Apheresis in Familial Hypercholesterolemia: Development and Application of a New Assay for PCSK9"],"prefix":"10.1210","volume":"100","author":[{"given":"Mika","family":"Hori","sequence":"first","affiliation":[{"name":"Department of Molecular Innovation in Lipidology (M.H., Y.Y., M.H-S.), National Cerebral and Cardiovascular Center Research Institute, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuaki","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Advanced Medical Technology and Development Division (M.I., T.K., H.H.), BML, Inc., 1361-1 Matoba, Kawagoe, Saitama 350-1101, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Yuasa","sequence":"additional","affiliation":[{"name":"Department of Molecular Innovation in Lipidology (M.H., Y.Y., M.H-S.), National Cerebral and Cardiovascular Center Research Institute, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Makino","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism (H.M., T.T., I.K.), National Cerebral and Cardiovascular Center, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Yanagi","sequence":"additional","affiliation":[{"name":"Department of Cardiology (K.Y.), Kenporen Osaka Central Hospital, Umeda 3-3-30, Kita-ku, Osaka 530-0001, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamiko","family":"Tamanaha","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism (H.M., T.T., I.K.), National Cerebral and Cardiovascular Center, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Kishimoto","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism (H.M., T.T., I.K.), National Cerebral and Cardiovascular Center, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kujiraoka","sequence":"additional","affiliation":[{"name":"Advanced Medical Technology and Development Division (M.I., T.K., H.H.), BML, Inc., 1361-1 Matoba, Kawagoe, Saitama 350-1101, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Hattori","sequence":"additional","affiliation":[{"name":"Advanced Medical Technology and Development Division (M.I., T.K., H.H.), BML, Inc., 1361-1 Matoba, Kawagoe, Saitama 350-1101, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Harada-Shiba","sequence":"additional","affiliation":[{"name":"Department of Molecular Innovation in Lipidology (M.H., Y.Y., M.H-S.), National Cerebral and Cardiovascular Center Research Institute, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071614180720900_B1","article-title":"Familial hypercholesterolemia","volume-title":"The Metabolic and Molecular Bases of Inherited Disease","author":"Goldstein","year":"2001","edition":"8th ed"},{"key":"2020071614180720900_B2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nature Genetics"},{"key":"2020071614180720900_B3","doi-asserted-by":"crossref","first-page":"48865","DOI":"10.1074\/jbc.M409699200","article-title":"NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol","volume":"279","author":"Benjannet","year":"2004","journal-title":"J Biol Chem"},{"key":"2020071614180720900_B4","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1073\/pnas.0402133101","article-title":"Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype","volume":"101","author":"Maxwell","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071614180720900_B5","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1194\/jlr.M900273-JLR200","article-title":"A new method for measurement of total plasma PCSK9: clinical applications","volume":"51","author":"Dubuc","year":"2010","journal-title":"J Lipid Res"},{"key":"2020071614180720900_B6","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1373\/clinchem.2007.091280","article-title":"Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol","volume":"53","author":"Alborn","year":"2007","journal-title":"Clin Chem"},{"key":"2020071614180720900_B7","doi-asserted-by":"crossref","first-page":"30561","DOI":"10.1074\/jbc.M606495200","article-title":"The proprotein convertase (PC) PCSK9 is inactivated by furin and\/or PC5\/6A: functional consequences of natural mutations and post-translational modifications","volume":"281","author":"Benjannet","year":"2006","journal-title":"J Biol Chem"},{"key":"2020071614180720900_B8","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1074\/jbc.M110.192104","article-title":"In vivo evidence that furin from hepatocytes inactivates PCSK9","volume":"286","author":"Essalmani","year":"2011","journal-title":"J Biol Chem"},{"key":"2020071614180720900_B9","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1194\/jlr.M049346","article-title":"Isolation and characterization of the circulating truncated form of PCSK9","volume":"55","author":"Han","year":"2014","journal-title":"J Lipid Res"},{"key":"2020071614180720900_B10","doi-asserted-by":"crossref","first-page":"43482","DOI":"10.1074\/jbc.M112.380618","article-title":"Furin-cleaved proprotein convertase subtilisin\/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels","volume":"287","author":"Lipari","year":"2012","journal-title":"J Biol Chem"},{"key":"2020071614180720900_B11","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1161\/01.ATV.5.6.613","article-title":"Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia","volume":"5","author":"Yokoyama","year":"1985","journal-title":"Arteriosclerosis"},{"key":"2020071614180720900_B12","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1046\/j.1526-0968.2003.00073.x","article-title":"Long-term effect of low-density lipoprotein apheresis in patients with homozygous familial hypercholesterolemia","volume":"7","author":"Makino","year":"2003","journal-title":"Ther Apher Dial"},{"key":"2020071614180720900_B13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0009-8981(02)00103-1","article-title":"Single LDL apheresis improves serum remnant-like particle-cholesterol, C-reactive protein, and malondialdehyde-modified-low-density lipoprotein concentrations in Japanese hypercholesterolemic subjects","volume":"321","author":"Kobayashi","year":"2002","journal-title":"Clin Chim Acta"},{"key":"2020071614180720900_B14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/039139889201500309","article-title":"Changes in coagulation factors by passage through a dextran sulfate cellulose column during low-density lipoprotein apheresis","volume":"15","author":"Kojima","year":"1992","journal-title":"Int J Artif Organs"},{"key":"2020071614180720900_B15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/1744-9987.12056","article-title":"Proteomic analysis of proteins eliminated by low-density lipoprotein apheresis","volume":"18","author":"Yuasa","year":"2014","journal-title":"Ther Apher Dial"},{"key":"2020071614180720900_B16","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1161\/CIRCRESAHA.113.302655","article-title":"Loss of plasma proprotein convertase subtilisin\/kexin 9 (PCSK9) after lipoprotein apheresis","volume":"113","author":"Tavori","year":"2013","journal-title":"Circ Res"},{"key":"2020071614180720900_B17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.trsl.2012.01.010","article-title":"Serum levels of proprotein convertase subtilisin\/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin\/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways","volume":"160","author":"Cameron","year":"2012","journal-title":"Transl Res"},{"key":"2020071614180720900_B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0021-9150(86)90107-3","article-title":"Causes of death in patients with familial hypercholesterolemia","volume":"61","author":"Mabuchi","year":"1986","journal-title":"Atherosclerosis"},{"key":"2020071614180720900_B19","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.5551\/jat.14621","article-title":"Guidelines for the management of familial hypercholesterolemia","volume":"19","author":"Harada-Shiba","year":"2012","journal-title":"J Atheroscler Thromb"},{"key":"2020071614180720900_B20","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1210\/jc.2002-021487","article-title":"Clinical features and genetic analysis of autosomal recessive hypercholesterolemia","volume":"88","author":"Harada-Shiba","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614180720900_B21","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1194\/jlr.D500018-JLR200","article-title":"A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration","volume":"46","author":"Ishihara","year":"2005","journal-title":"J Lipid Res"},{"key":"2020071614180720900_B22","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/S0022-2275(20)31998-2","article-title":"Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive","volume":"41","author":"Oka","year":"2000","journal-title":"J Lipid Res"},{"key":"2020071614180720900_B23","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","article-title":"Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia","volume":"24","author":"Dubuc","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2020071614180720900_B24","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1194\/jlr.M003566","article-title":"Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters","volume":"51","author":"Dong","year":"2010","journal-title":"J Lipid Res"},{"key":"2020071614180720900_B25","doi-asserted-by":"crossref","first-page":"11915","DOI":"10.1073\/pnas.0805434105","article-title":"Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates","volume":"105","author":"Frank-Kamenetsky","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071614180720900_B26","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1038\/mtna.2012.16","article-title":"Cholesterol-lowering action of BNA-based antisense oligonucleotides targeting PCSK9 in atherogenic diet-induced hypercholesterolemic mice","volume":"1","author":"Yamamoto","year":"2012","journal-title":"Mol Therapy Nucleic Acids"},{"key":"2020071614180720900_B27","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1073\/pnas.0903849106","article-title":"A proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates","volume":"106","author":"Chan","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071614180720900_B28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","article-title":"Effect of a monoclonal antibody to PCSK9, REGN727\/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial","volume":"380","author":"Stein","year":"2012","journal-title":"Lancet"},{"key":"2020071614180720900_B29","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"key":"2020071614180720900_B30","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.amjcard.2013.01.289","article-title":"Comparison of effects of pitavastatin versus pravastatin on serum proprotein convertase subtilisin\/kexin type 9 levels in statin-na\u00efve patients with coronary artery disease","volume":"111","author":"Nozue","year":"2013","journal-title":"Am J Cardiol"},{"key":"2020071614180720900_B31","doi-asserted-by":"crossref","first-page":"8279","DOI":"10.1074\/jbc.M112.421370","article-title":"Low density lipoprotein binds to proprotein convertase subtilisin\/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation","volume":"288","author":"Kosenko","year":"2013","journal-title":"J Biol Chem"},{"key":"2020071614180720900_B32","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1161\/CIRCULATIONAHA.113.001592","article-title":"Serum proprotein convertase subtilisin\/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation","volume":"127","author":"Tavori","year":"2013","journal-title":"Circulation"},{"key":"2020071614180720900_B33","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1161\/ATVBAHA.112.250043","article-title":"Proprotein convertase subtilisin\/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor","volume":"32","author":"Sun","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2020071614180720900_B34","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1021\/bi7016359","article-title":"Self-association of human PCSK9 correlates with its LDLR-degrading activity","volume":"47","author":"Fan","year":"2008","journal-title":"Biochemistry"},{"key":"2020071614180720900_B35","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.bbalip.2013.06.004","article-title":"Aging affects high-density lipoprotein composition and function","volume":"1831","author":"Holzer","year":"2013","journal-title":"Biochim Biophys Acta"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/100\/1\/E41\/9096181\/jcem0E41.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/100\/1\/E41\/9096181\/jcem0E41.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T23:26:17Z","timestamp":1650410777000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/100\/1\/E41\/2812856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2014-3066","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,1]]}}}